As pointed out by Sorigue et al. [1] in their letter related to our work [2], follicular lymphoma (FL) grade 3A and 3B is managed in Europe to some extent differently to China and the United States. In their letter, Sorigue et al. emphasize that this setting of clinical borders is not evidence-based. We agree with this comment and like to add that these treatment recommendations were developed from historical classifications before the WHO classification in 2001 implemented grading of FL.